Accuray Incorporated Company Profile (NASDAQ:ARAY)

About Accuray Incorporated (NASDAQ:ARAY)

Accuray Incorporated logoAccuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:ARAY
  • CUSIP: 00439710
  • Web:
  • Market Cap: $344.45 million
  • Outstanding Shares: 83,000,000
Average Prices:
  • 50 Day Moving Avg: $4.38
  • 200 Day Moving Avg: $4.93
  • 52 Week Range: $3.85 - $6.39
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -29.64
  • P/E Growth: 0.05
Sales & Book Value:
  • Annual Revenue: $366.29 million
  • Price / Sales: 0.94
  • Book Value: $0.55 per share
  • Price / Book: 7.55
  • EBIDTA: ($5,100,000.00)
  • Net Margins: -6.88%
  • Return on Equity: -46.38%
  • Return on Assets: -5.73%
  • Debt-to-Equity Ratio: 3.57%
  • Current Ratio: 1.76%
  • Quick Ratio: 1.11%
  • Average Volume: 894,786 shs.
  • Beta: 1.58
  • Short Ratio: 8.86

Frequently Asked Questions for Accuray Incorporated (NASDAQ:ARAY)

What is Accuray Incorporated's stock symbol?

Accuray Incorporated trades on the NASDAQ under the ticker symbol "ARAY."

How were Accuray Incorporated's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) announced its quarterly earnings data on Thursday, April, 27th. The company reported ($0.06) EPS for the quarter, missing the Zacks' consensus estimate of $0.01 by $0.07. The company had revenue of $97.31 million for the quarter, compared to analyst estimates of $110.23 million. Accuray Incorporated had a negative return on equity of 46.38% and a negative net margin of 6.88%. The business's quarterly revenue was down 7.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.01 earnings per share. View Accuray Incorporated's Earnings History.

Where is Accuray Incorporated's stock going? Where will Accuray Incorporated's stock price be in 2017?

6 brokers have issued 1-year target prices for Accuray Incorporated's shares. Their forecasts range from $6.00 to $9.00. On average, they anticipate Accuray Incorporated's stock price to reach $7.40 in the next year. View Analyst Ratings for Accuray Incorporated.

What are analysts saying about Accuray Incorporated stock?

Here are some recent quotes from research analysts about Accuray Incorporated stock:

  • 1. According to Zacks Investment Research, "Accuray reported wider-than-expected loss in the third quarter of fiscal 2017, primarily due to declining product revenues. Also, over the past one year, the company underperformed the broader industry with respect to price. Of the recent developments, orders for the newly unveiled Radixact System, solid revenue performance in Japan, and Japanese regulatory approval for Radixact are key positives in our view. We believe a broad product portfolio, growing customer base, stringent cost control and international expansion will drive growth. However, a drop in gross orders, unfavorable product mix, declining product and service revenues, sluggish macro economic conditions and pricing headwinds are major concerns. Notably, China and Europe saw sluggish revenues in the third quarter." (5/16/2017)
  • 2. BTIG Research analysts commented, "Concerning; Guidance Lowered as Predicted; Neutral Accuray showed strong order growth in the quarter driven by a mix of Cyberknife, Radixact and a modest contribution from On-Rad across multiple geographies. While gross orders were strong, the revenue was significantly below expectations and, just as we predicted, revenue guidance for FY17 was lowered $30M to $380M to $390M from $410M to $420M previously (we modeled $395M heading into the print). ARAY is seeing a large proportion of orders OUS and into distributors with limited lines of sight on when those orders begin to convert to revenue which makes it challenging, not only to guide from mgmt.’s viewpoint, but also tough to model from our perspective. The company undertook a restructuring in the Q to improve these processes but we feel this will take multiple quarters to improve. Many companies within MedTech rely on OUS distributors but have limited predictability on sales OUS and we do not believe ARAY is immune to those challenges. All told, we maintain our Neutral rating and need to see revenue conversion consistently.   Soft GMs limit improvements in adjusted EBITDA growth. Mgmt has undertaken steps to improve COGS but volume swings in units continue to impact gross margins Q-to-Q. GMs came in 400bps below our expectations and will come in at ~37% for FY17. We expect GMs to remain in the low 40s in FY18 and beyond. Adj. EBTIDA guidance for FY17 was also lowered to $22M to $26M from $32M to $38M driven by the lowered revenue and soft GMs." (4/30/2017)
  • 3. Aegis analysts commented, "The company has been successful in shifting gears to the smaller vault centers, re-positioning TomoTherapy as a work horse machine. Accuray has moved outside of the niche high-end large academic centers into the broader single- and dual-vault centers, with single- and dual-vault centers now accounting for 50% of new TomoTherapy orders (up from 0% in 2012).He added, "Radixact, the next-generation TomoTherapy platform, was approved for 510k in June (CE Mark in Aug) and brings ARAY up to par with Varian's TrueBeam and Elekta's Axesse machines. Radixact adds higher output dosing along with integrated treatment planning (Precision') and data management (iDMS') systems that will increase the ease and speed of systems, and should have its full launch in time for ARAYs first major replacement cycle. The reliability issues previously associated with TomoTherapy are now behind them, and Tomo is consistantly ranked #1 in overall system performance by ServiceTrak." (2/6/2017)

Are investors shorting Accuray Incorporated?

Accuray Incorporated saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 8,003,517 shares, an increase of 5.6% from the April 13th total of 7,581,417 shares. Based on an average trading volume of 727,267 shares, the days-to-cover ratio is currently 11.0 days.

Who are some of Accuray Incorporated's key competitors?

Who owns Accuray Incorporated stock?

Accuray Incorporated's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), Primecap Management Co. CA (0.00%), Neuberger Berman Group LLC (0.00%), Renaissance Technologies LLC (0.00%), PARTNER FUND MANAGEMENT, L.P. (5.00%) and Heartland Advisors Inc. (4.28%). View Institutional Ownership Trends for Accuray Incorporated.

Who sold Accuray Incorporated stock? Who is selling Accuray Incorporated stock?

Accuray Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, North Tide Capital LLC, Russell Investments Group Ltd., Parametric Portfolio Associates LLC, Schwab Charles Investment Management Inc., Cornerstone Capital Management Holdings LLC., Morgan Stanley and Wellington Management Group LLP. View Insider Buying and Selling for Accuray Incorporated.

Who bought Accuray Incorporated stock? Who is buying Accuray Incorporated stock?

Accuray Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Vident Investment Advisory LLC, Bogle Investment Management L P DE, Vanguard Group Inc., Dimensional Fund Advisors LP, Menta Capital LLC, UBS Group AG and First Trust Advisors LP. View Insider Buying and Selling for Accuray Incorporated.

How do I buy Accuray Incorporated stock?

Shares of Accuray Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Accuray Incorporated stock cost?

One share of Accuray Incorporated stock can currently be purchased for approximately $4.15.

Analyst Ratings

Consensus Ratings for Accuray Incorporated (NASDAQ:ARAY) (?)
Ratings Breakdown: 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $7.40 (78.31% upside)

Analysts' Ratings History for Accuray Incorporated (NASDAQ:ARAY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/30/2017BTIG ResearchReiterated RatingHoldMediumView Rating Details
4/29/2017Jefferies Group LLCReiterated RatingBuy$8.00 -> $7.00LowView Rating Details
3/21/2017AegisReiterated RatingBuyMediumView Rating Details
12/14/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$8.00 -> $6.00N/AView Rating Details
9/13/2016Cowen and CompanyInitiated CoverageOutperform$9.00N/AView Rating Details
8/18/2016Morgan StanleySet Price TargetHold$8.00N/AView Rating Details
5/22/2016Brean CapitalReiterated RatingBuy$12.00N/AView Rating Details
1/29/2016Royal Bank of CanadaLower Price TargetSector Perform$8.00 -> $7.50N/AView Rating Details
11/12/2015Citigroup IncInitiated CoverageSellN/AView Rating Details
(Data available from 5/28/2015 forward)


Earnings History for Accuray Incorporated (NASDAQ:ARAY)
Earnings by Quarter for Accuray Incorporated (NASDAQ:ARAY)
Earnings History by Quarter for Accuray Incorporated (NASDAQ:ARAY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q3 2017$0.01($0.06)$110.23 million$97.31 millionViewN/AView Earnings Details
1/31/2017Q217($0.09)($0.11)$93.74 million$87.50 millionViewListenView Earnings Details
10/27/2016Q117($0.10)($0.12)$37.34 million$86.50 millionViewListenView Earnings Details
8/17/2016Q316($0.07)($0.09)$98.97 million$95.00 millionViewListenView Earnings Details
4/26/2016Q316($0.06)$0.01$102.79 million$105.30 millionViewListenView Earnings Details
1/28/2016Q216($0.08)($0.08)$101.15 million$108.90 millionViewListenView Earnings Details
10/29/2015Q116($0.14)($0.12)$88.60 million$89.60 millionViewListenView Earnings Details
8/20/2015Q415($0.04)($0.07)$102.41 million$101.80 millionViewListenView Earnings Details
4/30/2015Q315($0.06)($0.04)$102.72 million$97.50 millionViewListenView Earnings Details
1/27/2015Q215($0.08)($0.13)$98.87 million$98.20 millionViewListenView Earnings Details
10/29/2014Q115($0.13)($0.28)$88.90 million$82.40 millionViewListenView Earnings Details
8/21/2014Q414($0.07)($0.13)$92.23 million$102.00 millionViewListenView Earnings Details
4/30/2014Q314($0.16)($0.06)$82.00 million$97.10 millionViewListenView Earnings Details
1/30/2014Q214($0.20)($0.07)$80.20 million$93.60 millionViewListenView Earnings Details
11/7/2013Q114($0.20)($0.21)$79.67 million$76.60 millionViewListenView Earnings Details
8/27/2013Q4 2013($0.20)($0.20)$82.29 million$84.90 millionViewListenView Earnings Details
5/7/2013Q3 2013($0.22)($0.37)$77.97 million$70.55 millionViewListenView Earnings Details
2/6/2013Q2 2013($0.33)($0.30)$74.23 million$77.80 millionViewListenView Earnings Details
11/7/2012Q113($0.22)($0.23)$85.41 million$83.00 millionViewN/AView Earnings Details
9/6/2012Q412($0.12)($0.20)$106.92 million$100.50 millionViewN/AView Earnings Details
5/8/2012($0.14)($0.21)ViewN/AView Earnings Details
11/8/2011($0.29)($0.38)ViewN/AView Earnings Details
9/19/2011$0.02($0.40)ViewN/AView Earnings Details
5/5/2011$0.04($0.02)ViewN/AView Earnings Details
1/27/2011($0.01)$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Accuray Incorporated (NASDAQ:ARAY)
2017 EPS Consensus Estimate: ($0.12)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.06)($0.06)($0.06)
Q3 20171$0.02$0.02$0.02
Q4 20171$0.02$0.02$0.02
(Data provided by Zacks Investment Research)


Dividend History for Accuray Incorporated (NASDAQ:ARAY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Accuray Incorporated (NASDAQ:ARAY)
Insider Ownership Percentage: 2.91%
Institutional Ownership Percentage: 91.66%
Insider Trades by Quarter for Accuray Incorporated (NASDAQ:ARAY)
Institutional Ownership by Quarter for Accuray Incorporated (NASDAQ:ARAY)
Insider Trades by Quarter for Accuray Incorporated (NASDAQ:ARAY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2015Joshua LevineCEOBuy50,000$7.12$356,000.00View SEC Filing  
2/2/2015Alaleh NouriSVPSell5,164$7.38$38,110.32View SEC Filing  
11/30/2014Alaleh NouriSVPSell268$6.62$1,774.16View SEC Filing  
11/30/2014Kelly LondyEVPSell2,273$6.62$15,047.26View SEC Filing  
11/3/2014Joshua LevineCEOBuy100,000$6.34$634,000.00View SEC Filing  
5/6/2014Joshua LevineCEOBuy50,000$8.15$407,500.00View SEC Filing  
2/4/2014Richard PettingillDirectorBuy9,795$10.33$101,182.35View SEC Filing  
12/4/2013Jack GoldsteinDirectorSell7,000$7.70$53,900.00View SEC Filing  
12/3/2013Elizabeth DavilaDirectorSell8,000$7.74$61,920.00View SEC Filing  
9/4/2013Darren J MillikenSVPSell11,002$6.53$71,843.06View SEC Filing  
3/5/2013Dennis L WingerDirectorBuy20,000$4.30$86,000.00View SEC Filing  
2/13/2013Joshua LevineCEOBuy100,000$4.38$438,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Accuray Incorporated (NASDAQ:ARAY)
Latest Headlines for Accuray Incorporated (NASDAQ:ARAY)
DateHeadline logoWeakness Seen in Accuray (ARAY) Estimates: Should You Stay Away? - Nasdaq - May 26 at 3:52 PM logoWeakness Seen in Accuray (ARAY) Estimates: Should You Stay Away? - May 26 at 3:52 PM logoAccuray Incorporated (ARAY) Receives Consensus Recommendation of "Hold" from Brokerages - May 26 at 9:21 AM logoFive charged with insider trading involving U.S. health agency - May 24 at 3:34 PM logoAccuray Appoints Stan Gee VP of Revenue Management - May 24 at 8:50 AM logoAccuray Incorporated (ARAY) Downgraded by Zacks Investment Research to "Sell" - May 16 at 6:58 PM logoShort Interest in Accuray Incorporated (ARAY) Grows By 5.6% - May 15 at 8:48 AM logoAccuray (ARAY) Announces New Data on Versatility & Precision of CyberKnife® System at ESTERO Meetings - May 11 at 3:59 PM logoNew Data Presented at ESTRO 36 Reinforce Unmatched Versatility and Precision of the CyberKnife® System - May 11 at 3:59 PM logoNew Data Reinforce Benefits of TomoTherapy® Platform for Mainstream Radiation Therapy Treatment Indications - May 11 at 3:59 PM logoAccuray Incorporated (ARAY) Expected to Post Quarterly Sales of $111.45 Million - May 10 at 11:34 AM logoAccuray to Showcase CyberKnife® and Radixact™ Systems at ESTRO 2017 - May 3 at 9:44 AM logoAccuray (ARAY) Given Daily News Sentiment Score of 0.04 - May 2 at 7:28 PM logoAccuray (ARAY) Says Prelim. Results Show CyberKnife System Provides Effective Treatment Option for Early Stage ... - - May 2 at 8:45 AM logoCyberKnife® System Provides Effective Treatment Option with Minimal Side Effects and Excellent Cosmesis for Early Stage Breast Cancer Patients - May 2 at 8:45 AM logoToday's Research Reports on Stocks to Watch: Accuray and Align Technology - May 2 at 8:45 AM logoAccuray Incorporated (ARAY) Expected to Post FY2019 Earnings of $0.06 Per Share - May 1 at 3:04 PM logoAccuray Incorporated (ARAY) Given Consensus Recommendation of "Buy" by Brokerages - May 1 at 12:04 PM logoAccuray's (ARAY) "Hold" Rating Reaffirmed at BTIG Research - April 30 at 7:34 AM logoAccuray Incorporated (ARAY) Receives "Buy" Rating from Jefferies Group LLC - April 29 at 8:40 PM logoSomewhat Positive News Coverage Likely to Affect Accuray (ARAY) Share Price - April 29 at 12:29 PM logoPre-Open Movers 04/288: (ALGN) (SRPT) (WDC) Higher; (FCEL) (ATHN) (SYF) Lower (more...) - April 28 at 4:34 PM logoEdited Transcript of ARAY earnings conference call or presentation 27-Apr-17 8:30pm GMT - April 28 at 4:34 PM logoAccuray FQ3 revenues down 8%; loss of $5M; shares down 11% premarket on lowered guidance - April 28 at 9:30 AM logoAccuray's (ARAY) CEO Joshua Levine on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha - April 28 at 2:00 AM logoAccuray Incorporated (ARAY) Posts Earnings Results, Misses Estimates By $0.07 EPS - April 27 at 10:27 PM logoAccuray Updates Guidance - Quick Facts - April 27 at 9:00 PM logoEARNINGS SUMMARY: Details of Accuray Incorporated Q3 Earnings Report - April 27 at 9:00 PM logoAccuray Third Quarter Gross Orders Increase 49% YoY; Backlog Up 21% - April 27 at 9:00 PM logoAccuray Names Lionel Hadjadjeba Chief Commercial Officer - April 27 at 9:00 PM logoAccuray reports 3Q loss - April 27 at 9:00 PM logoAccuray (ARAY) Earning Somewhat Positive News Coverage, Analysis Shows - April 26 at 3:20 PM logoAccuray (ARAY) Given Daily Media Impact Score of 0.09 - April 23 at 8:22 AM logoAccuray (ARAY) Getting Somewhat Favorable News Coverage, Report Finds - April 20 at 2:40 PM logoETFs with exposure to Accuray, Inc. : April 19, 2017 - April 19 at 3:37 PM logoZacks: Brokerages Anticipate Accuray Incorporated (ARAY) Will Post Quarterly Sales of $116.71 Million - April 19 at 11:39 AM logo Brokerages Anticipate Accuray Incorporated (ARAY) to Post $0.03 Earnings Per Share - April 17 at 1:32 PM logoFavorable Media Coverage Somewhat Likely to Effect Accuray (ARAY) Share Price - April 14 at 4:40 PM logoIs Accuray (ARAY) a Great Growth Stock? - Yahoo Finance - April 13 at 3:47 PM logoAccuray To Report Fiscal 2017 Third Quarter Financial Results On April 27, 2017 - April 13 at 3:47 PM logoIs Accuray (ARAY) a Great Growth Stock? - April 13 at 3:47 PM logoAccuray 2017 Regional AERO Summit Brings Together Leading Oncology Specialists to Advance Cancer Patient Care - April 12 at 11:46 AM logoAccuray (ARAY) Says First Cancer Patients in Africa Treated with TomoTherapy System - - April 11 at 8:04 AM logoFirst Cancer Patients in Africa Treated with the TomoTherapy® System - April 11 at 8:03 AM logoAccuray Incorporated (ARAY) Upgraded by Zacks Investment Research to "Buy" - April 4 at 3:09 PM logoAccuray Incorporated (ARAY) Receives Average Rating of "Buy" from Analysts - April 4 at 12:40 PM logoAccuray's (ARAY) Buy Rating Reaffirmed at Aegis - March 23 at 6:25 PM logoACCURAY INC Files SEC form 8-K, Entry into a Material Definitive Agreement - March 10 at 9:22 PM logoNorth Tide Capital, Llc Buys Impax Laboratories, Allergan PLC, Accuray, Sells Community Health ... - March 3 at 3:51 PM logoAccuray Launches New Cancer Patient Websites - March 2 at 3:52 PM



Accuray Incorporated (ARAY) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff